Last reviewed · How we verify
NCT05219123
Guidewire Management in ERCP
trial testing ERCP with no PD cannulation in ERCP in 7,461 participants. Completed in 9 December 2024.
9 December 2024
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 7,461 |
| Start date | 20 December 2021 |
| Primary completion | 9 December 2024 |
| Estimated completion | 9 December 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- ERCP with no PD cannulation
- ERCP with single PD cannulation
Conditions studied
- ERCP — all drugs for ERCP →
Sponsor
University of Calgary
Who can join
18 and older, any sex, with ERCP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Intra-procedural guidewire management is a parameter whose impact remains incompletely understood in terms of its association with post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Inadvertent guidewire cannulation of the pancreatic duct (PD) when attempting common bile duct (CBD) cannulation is recognized as a risk factor for PEP. However, to date, no studies have assessed whether a single PD wire cannulation is associated with a higher PEP risk compared to no PD cannulations. Similarly, the relationship between each additional PD cannulation and the incremental magnitude of PEP risk remains unclear. In this study, the investigators will aim to assess whether a single inadvertent PD cannulation (versus no PD cannulation) is associated with an increased risk of PEP (the primary outcome).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05219123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ERCP
Currently open trials in the same condition.
- NCT07368335 — Efficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone · NA · active not recruiting
- NCT07244432 — Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS) · recruiting
- NCT07056075 — Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP · NA · recruiting
- NCT07071441 — Indomethacin vs Diclofenac for Preventing PEP · NA · recruiting
- NCT07130864 — Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp. · NA · recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05219123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 20 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05219123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing